Pharmacotherapy for squamous-cell carcinoma of the head and neck

Author： Papaspyrou Giorgos Werner Jochen A Dietz Andreas

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.3, 2011-02, pp. : 397-409

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Afatinib in the treatment of head and neck squamous cell carcinoma

By Ferrarotto Renata Gold Kathryn A

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 1, 2014-01 ,pp. : 135-143

Informa Healthcare

Access to resources Recommend Favorite

Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma

Current Molecular Pharmacology, Vol. 9, Iss. 3, 2016-08 ,pp. : 226-230

Bentham Science Publishers

Access to resources Recommend Favorite

Cisplatin + capecitabine active in head, neck squamous cell carcinoma

Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Cetuximab: A Review of its Use in Squamous Cell Carcinoma of the Head and Neck

By Frampton James E.

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 1987-2010

Adis International

Access to resources Recommend Favorite

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma

By Sundvall Maria Karrila Anna Nordberg Janne Grénman Reidar Elenius Klaus

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 2, 2010-06 ,pp. : 185-201

Informa Healthcare

Access to resources Recommend Favorite